ArticleEuropean heart journal. Quality of care & clinical outcomes2026
First clinical experience with the Transthyretin Amyloidosis-Quality of Life questionnaire (ATTR-QoL): associations with clinical characteristics and established patient-reported outcomes.
Article in European heart journal. Quality of care & clinical outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psycho-Emotional Profile and Disease Burden in Wild-Type Transthyretin Amyloidosis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsTransthyretin amyloidosis (ATTR) is a multisystemic disease impacting quality of life (QOL) through various symptoms. The Transthyretin Amyloidosis-Quality of Life Questionnaire (ATTR-QOL) was developed to assess disease-specific effects on QOL, but its associations with established patient-reported outcomes measures (PROs), clinical markers, and functional tests remain unexplored. METHODS AND
resultsThis cross-sectional study included consecutive ATTR patients at Columbia University between 3/2024 and 1/2025 who completed the ATTR-QOL. The questionnaire includes 5 symptom and 4 impact scores (range: 0-100, higher scores indicate worse status). Clinical parameters, PROs, and functionality were recorded at the same visit. PROs of interest included the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF36v2 and Composite Autonomic Symptom Score-31 (COMPASS-31), while 6-minute walk test and Short Physical Performance Battery Test were recorded as functionality measures. 194 patients (137 cardiomyopathy, 48 mixed, 9 neuropathy) were included. Most had early-stage disease [National Amyloidosis Centre (NAC) Stage 1: 70%, Stage 2: 22%, Stage 3: 8%], and all were on disease-modifying treatment. ATTR-QOL exhibited good convergent validity with clinical parameters, functionality testing, and established QOL tools. Additionally, ATTR-QOL demonstrated strong known-groups discriminant validity, as evidenced by its ability to differentiate between various clinical and functional groups, as well as established patient-reported outcome (PRO) categories.
conclusionATTR-QOL, as a disease-specific PRO, effectively captures the multidimensional impact of ATTR and is associated with clinical parameters and functionality in patients with ATTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.